Aspire Biopharma Holdings, Inc. (ASBP)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 2K | 4K | 28K | 63K |
| Gross Profit | 884.00 | (1K) | 6K | (30K) |
| Operating Income | (1.1M) | (1.8M) | (1.6M) | (2.4M) |
| Net Income | (1.9M) | (4.7M) | (3.2M) | (1.3M) |
| Diluted EPS | $-48.00 | N/A | $-20.57 | $-1.22 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 6K |
| Gross Profit | 0.00 | 0.00 | 0.00 | (116.00) |
| Operating Income | (596K) | (1.3M) | (1.2M) | (19.4M) |
| Net Income | (597K) | 4.5M | (1.3M) | (24.5M) |
| Diluted EPS | $-15.57 | $116.44 | $-34.17 | $-491.40 |